Srihari S. Naidu is an American physician and Professor of Medicine at New York Medical College who is known for his work on hypertrophic cardiomyopathy including the procedure known as alcohol septal ablation, and for helping to construct the universal diagnostic criteria for cardiogenic shock.

Career

An academic interventional cardiologist, Naidu is an expert in the management of patients with hypertrophic cardiomyopathy,[1] including the minimally-invasive alternative to surgery known as alcohol septal ablation.[2][3][4] A co-author on the first ACC/AHA National Guideline on the Diagnosis and Management of Hypertrophic Cardiomyopathy in 2011, he is editor of the international textbook on the disease,[5][6] runs a Hypertrophic Cardiomyopathy Treatment Center following over 2000 patients, and has personally performed over 275 alcohol septal ablations, believed to be the largest case series of this procedure by a single-operator in the United States. Hypertrophic cardiomyopathy is the most common cause of sudden cardiac death among athletes, and an increasingly recognized cause of heart failure at all ages.[7]

Naidu is Director of the Cardiac Cath Lab and Hypertrophic Cardiomyopathy Center - with offices in Long Island and Westchester - at Westchester Medical Center in Valhalla, NY. He is a two-term Past Member of the American College of Cardiology (ACC) Interventional Scientific Council and has served on the Program Committee for the American Heart Association Annual Scientific Sessions. He is the author of over 200 original scientific manuscripts, and has authored clinical practice guidelines and consensus statements on behalf of the American College of Cardiology (ACC), American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI), including Chairing the Best Practices in the Cardiac Catheterization Laboratory document since 2012 that outlines operations for cardiac catheterization laboratories in the United States.[8] Naidu is Founder and Past Chair of the Emerging Leader Mentorship (ELM) Program for SCAI (in partnership with ACC and the Cardiovascular Research Foundation), a national leadership pipeline initiated in 2010 that identifies and trains 12 interventional cardiologists every two years.[9][10]

Naidu is a 2-term Trustee of the Society for Cardiovascular Angiography and Interventions, the primary international professional society for physicians specializing in interventional cardiology, and was inducted into the International Andreas Gruentzig Society in 2016. An alum of the Brown University 8-year Program in Liberal Medical Education, Naidu is Past President of the Alpert Medical School of Brown University Alumni Association Board of Directors, and a Trustee Emeritus of Brown University,.[11]

In 2019, he was elected Governor and President of The New York State Chapter of the American College of Cardiology, and President of The New York Cardiological Society, which he will continue until 2024. In 2021 he was named to the Top 100 Notable Leaders in NY Healthcare in Crain's New York Business for his work in the national cardiovascular response to COVID-19. In 2022, he was elected Secretary of SCAI, is currently Vice President of the Society, and will be President from 2025-2026.

Personal life

Naidu lives in Manhattan, New York.

References

  1. ↑ Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Circulation. 2011 Dec 13;124(24):2761-96. doi: 10.1161/CIR.0b013e318223e230. Epub 2011 Nov 8.
  2. ↑ Khouzam RN, Naidu SS. Alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in patients with prior coronary revascularization. J Invasive Cardiol 2010;22(12):220-224.
  3. ↑ Juliano N, Wong SC, Naidu SS. Alcohol septal ablation for failed surgical myectomy. J Invasive Cardiol 2005;17(10):569-571.
  4. ↑ Polin N, Feldman D, Naidu SS. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Novel application of the cutting balloon. J Invasive Cardiol 2006;18(9):436-437.
  5. ↑ Naidu SS. Rethinking the selection criteria for alcohol septal ablation - is it time to push the envelope? J Invasive Cardiol 2010;22(12):592-3.
  6. ↑ Naidu SS, Editor. Hypertrophic Cardiomyopathy; Springer UK; https://www.amazon.co.uk/Hypertrophic-Cardiomyopathy-Srihari-Naidu/dp/1447149556
  7. ↑ https://www.winthrop.org/departments/clinical/cardiology/hypertrophic-cardiomyopathy-center/
  8. ↑ Naidu SS, Rao SV, Blankenship J, et al. SCAI Clinical Expert Consensus Statement on Best Practices in the Cardiac Catheterization Laboratory. Catheter Cardiovasc Interv 2012;80(3):456-464.
  9. ↑ SCAI ELM Program, www.scai.org/ELM
  10. ↑ Naidu SS. Identifying and Inspiring Leadership in Interventional Cardiology: Update on the SCAI Emerging Leader Mentorship Program. Catheter Cardiovasc Interv 2012;80(5):850-1.
  11. ↑ Membership of the Brown University Corporation, http://brown.edu/about/administration/corporation/membership
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.